We were able to detect 100% of recurrences by ctDNA ahead of clinical recurrence, which included all lung metastases as well as other distant metastases,” said Emma Titmuss.

In patients with multiple myeloma (MM), serum concentration of chitinase 3-like protein-1 (CHI3L1) protein is correlated with disease severity and predicts disease progression, according to research ...

AJCC9V staging system showed superior hazard consistency, outcome prediction, and balance, but not hazard discrimination.

After transformation, survival rates varied by original cancer type, with the poorest prognosis for those transformed from CLL/SLL and from LPL/WM.

Launch prices for self-administered targeted anticancer therapies have grown precipitously,” researchers wrote.

Researchers sought to improve HBOC genetic testing in underserved areas through cancer risk assessment at mammography.

US researchers analyzed national death certificate data to compare trends in hepatocellular carcinoma (HCC)-related mortality and underlying etiologies of chronic liver disease linked to HCC-related ...

The tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment present major challenges to surgeons performing salvage RARP.

Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

This analysis indicates that proposed Medicaid reforms would have far-reaching consequences beyond federal budget savings, including negative health outcomes, economic losses, and health care system ...